Sarpogrelate, a 5-HT2A Receptor Antagonist, Protects the Retina From Light-Induced Retinopathy

Invest Ophthalmol Vis Sci. 2015 Jul;56(8):4560-9. doi: 10.1167/iovs.15-16378.

Abstract

Purpose: To determine if sarpogrelate, a selective 5-HT2A receptor antagonist, is protective against light-induced retinopathy in BALB/c mice.

Methods: BALB/c mice were dosed intraperitoneally with 5, 15, 30, 40, or 50 mg/kg sarpogrelate 48, 24, and 0 hours prior to bright light exposure (10,000 lux) as well as 24 and 48 hours after exposure. Additionally, a single injection regimen was evaluated by injecting mice with 50 mg/kg sarpogrelate once immediately prior to light exposure. To investigate the potential for additive effects of serotonin receptor agents, a combination therapy consisting of sarpogrelate (15 mg/kg) and 8-OH-DPAT (1 mg/kg) was evaluated with the 5-day treatment regimen. Neuroprotection was characterized by the preservation of retinal thickness and function, measured by spectral-domain optical coherence tomography (SD-OCT) and electroretinography (ERG), respectively.

Results: Mice that were light damaged and injected with saline had significantly reduced outer retinal thickness, total retinal thickness, and ERG amplitudes compared with naïve mice. A 5-day administration of 15, 30, or 40 mg/kg of sarpogrelate was able to partially protect retinal morphology and full protection of retinal morphology was achieved with a 50 mg/kg dose. Both 15 and 30 mg/kg doses of sarpogrelate partially preserved retinal function measured by ERG, whereas 40 and 50 mg/kg doses fully preserved retinal function. Additionally, a single administration of 50 mg/kg sarpogrelate was able to fully preserve both retinal morphology and function. Administration of 15 mg/kg of sarpogrelate and 1 mg/kg of 8-OH-DPAT together demonstrated an additive effect and fully preserved retinal morphology.

Conclusions: A 5- or 1-day treatment with 50 mg/kg sarpogrelate can completely protect the retina of BALB/c mice from light-induced retinopathy. Partial protection can be achieved with lower doses starting at 15 mg/kg and protection increases in a dose-dependent manner. Treatment with low doses of sarpogrelate and 8-OH-DPAT elicits an additive effect that results in full protection of retinal morphology.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 8-Hydroxy-2-(di-n-propylamino)tetralin / pharmacology
  • Animals
  • Disease Models, Animal
  • Electroretinography
  • Injections, Intraperitoneal
  • Light / adverse effects*
  • Mice
  • Mice, Inbred BALB C
  • Radiation Injuries, Experimental / etiology
  • Radiation Injuries, Experimental / pathology
  • Radiation Injuries, Experimental / prevention & control*
  • Radiation-Protective Agents / administration & dosage
  • Radiation-Protective Agents / therapeutic use*
  • Retina / pathology
  • Retina / radiation effects*
  • Retinal Degeneration / etiology
  • Retinal Degeneration / pathology
  • Retinal Degeneration / prevention & control*
  • Serotonin 5-HT2 Receptor Antagonists / administration & dosage
  • Serotonin 5-HT2 Receptor Antagonists / therapeutic use*
  • Serotonin Receptor Agonists / pharmacology
  • Succinates / administration & dosage
  • Succinates / therapeutic use*
  • Tomography, Optical Coherence

Substances

  • Radiation-Protective Agents
  • Serotonin 5-HT2 Receptor Antagonists
  • Serotonin Receptor Agonists
  • Succinates
  • sarpogrelate
  • 8-Hydroxy-2-(di-n-propylamino)tetralin